search
Back to results

Fine Needle Biopsy of Solid Pancreatic Mass Lesions

Primary Purpose

Pancreatic Neoplasms

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Solid pancreatic mass lesion biopsy
Sponsored by
AdventHealth
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Pancreatic Neoplasms focused on measuring pancreatic mass, pancreatic solid mass, pancreatic lesion

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. All patients referred for EUS-guided tissue acquisition of suspected or confirmed solid pancreatic mass lesions visualized on any radiological imaging
  2. Able and willing to provide written or verbal consent
  3. ≥ 18 years old
  4. Able to undergo conscious sedation for EUS procedure

Exclusion Criteria:

  1. <18 years old
  2. Unable to obtain informed consent from the patient
  3. Medically unfit for sedation
  4. Pregnant patients
  5. No pancreatic mass lesions visualized on EUS
  6. Irreversible coagulopathy as determined by platelet count < 50,000/microL or International Normalized Ratio (INR) > 1.5
  7. Unable to stop anti-platelet agents prior to the procedure

Sites / Locations

  • AdventHealth OrlandoRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Active Comparator

Active Comparator

Active Comparator

Arm Label

22 Gauge FNB Needle - ProCore

22 Gauge FNB Needle - Acquire

22 Gauge FNB Needle - SharkCore

22 Gauge FNB needle - EZ Shot 3 Plus

Arm Description

The 22 Gauge FNB Needle - ProCore will be used to biopsy solid pancreatic mass lesions.

The 22 Gauge FNB Needle - Acquire will be used to biopsy solid pancreatic mass lesions.

The 22 Gauge FNB Needle - SharkCore will be used to biopsy solid pancreatic mass lesions.

The 22 Gauge FNB Needle - EZ Shot 3 Plus will be used to biopsy solid pancreatic mass lesions.

Outcomes

Primary Outcome Measures

Degree of cellularity in biopsy sample
Compare the degree of cellularity of the obtained tissue in the biopsy sample between the four FNB needles in patients undergoing EUS-guided sampling of pancreatic masses using the three different sampling techniques. Cellularity is defined as the proportion of core tissue to total specimen area.

Secondary Outcome Measures

Diagnostic adequacy of the biopsy sample
Documentation of the presence of adequate tissue material (pancreatic parenchyma and tumor if applicable) in the biopsy sample.
Specimen bloodiness in biopsy sample
Measured as the area of bloodiness in the biopsy sample, with calculation as a percentage in the microscopic field.
Presence of crush artefact in biopsy sample
Documenting the presence or absence of crush artefact in the biopsy sample. If present, it is measured as the area of artefact in biopsy sample, with calculation as a percentage in relation to the total sample area.
Technical failure
Measured as the inability to successfully perform the fine needle biopsy using the assigned needle, due to any needle dysfunction.
Adverse events
The subject will be asked to report and medical records will be reviewed for any adverse events related to the procedure or the underlying disease.
Diagnostic operating characteristics
Compare the diagnostic operating characteristics of the biopsy sample and detection of neoplasia (defined as sensitivity, specificity, negative predictive value, positive predictive value and accuracy) between the four FNB needles in patients undergoing EUS-guided sampling of pancreatic masses using the three different sampling techniques

Full Information

First Posted
September 9, 2019
Last Updated
August 3, 2020
Sponsor
AdventHealth
search

1. Study Identification

Unique Protocol Identification Number
NCT04085055
Brief Title
Fine Needle Biopsy of Solid Pancreatic Mass Lesions
Official Title
Randomized Trial Comparing Fine Needle Biopsy Needles and Different Techniques for Endoscopic-guided Fine Needle Biopsy of Solid Pancreatic Mass Lesions
Study Type
Interventional

2. Study Status

Record Verification Date
August 2020
Overall Recruitment Status
Unknown status
Study Start Date
September 9, 2019 (Actual)
Primary Completion Date
June 25, 2020 (Actual)
Study Completion Date
December 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AdventHealth

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a randomized trial to evaluate and directly compare the tissue quality, diagnostic sucess and safety profile of four different Fine Needle Biopsy needles.
Detailed Description
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is currently the standard method for sampling solid pancreatic masses, with reported sensitivity for malignant cytology of 85-95%, specificity of 95-98% and diagnostic accuracy of 78-95%. Diagnostic failure of EUS-FNA can be due to inadequate targeting, inexperience of the endoscopist/pathologist, or necrotic or fibrotic tumors in which viable cells are difficult to obtain. The cellularity and architectural representation of the sample can also be determined by the needle used and its specific features. Recently, new needles known as "fine needle biopsy (FNB)" needles have become available that are specially designed to promote the collection of core tissue by unique designs of their needle tips. The advantages of FNB over FNA needles are that (a) the quality of tissue procured is superior: FNA needles yield cytology whereas FNB needles yield histology (b) molecular marker analysis can be performed more reliably on histology samples than cytology aspirates and (c) as histological tissue is greater in quantity than cytological aspirates, a quicker diagnosis with fewer passes can be established by histology than cytology. Four different types of FNB needles are currently available - reverse-bevel tip (EchoTip ProCore HD Ultrasound Biopsy Needle, Cook Medical, Bloomington, IN), Menghini-tip (EZ shot, Olympus America, Center Valley, PA), Franseen tip (Acquire, Boston Scientific Corporation, Natick, MA) and fork-tip (SharkCore, Medtronic Corporation/Covidien, Newton, MA) needles, each with unique tip designs to facilitate procurement of histological core tissue. Although we have previously compared in randomized trials the diagnostic yield of Franseen and fork-tip FNB needles and have shown the two needles to be equivalent, there are currently no randomized trials directly comparing all four FNB needle types. EUS-guided tissue acquisition can also be performed using different techniques, including the use of suction, no use of suction and the stylet retraction technique. There are currently no studies comparing these different tissue acquisition techniques using the different FNB needles and no study has demonstrated the best technique for FNB.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Neoplasms
Keywords
pancreatic mass, pancreatic solid mass, pancreatic lesion

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
This is a randomized trial comparing four types of FNB needles and three sampling techniques. Patients will be randomized to one of the four different FNB needles. All patients will then undergo FNB using the specified needle and all three sampling techniques (one pass per technique using the assigned needle).
Masking
ParticipantCare ProviderOutcomes Assessor
Masking Description
The patients, pathologists assessing the biopsy specimens and the research staff responsible for follow-up will be blinded to the FNB needle type utilized. Data will also be blinded for statistical analysis.
Allocation
Randomized
Enrollment
130 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
22 Gauge FNB Needle - ProCore
Arm Type
Active Comparator
Arm Description
The 22 Gauge FNB Needle - ProCore will be used to biopsy solid pancreatic mass lesions.
Arm Title
22 Gauge FNB Needle - Acquire
Arm Type
Active Comparator
Arm Description
The 22 Gauge FNB Needle - Acquire will be used to biopsy solid pancreatic mass lesions.
Arm Title
22 Gauge FNB Needle - SharkCore
Arm Type
Active Comparator
Arm Description
The 22 Gauge FNB Needle - SharkCore will be used to biopsy solid pancreatic mass lesions.
Arm Title
22 Gauge FNB needle - EZ Shot 3 Plus
Arm Type
Active Comparator
Arm Description
The 22 Gauge FNB Needle - EZ Shot 3 Plus will be used to biopsy solid pancreatic mass lesions.
Intervention Type
Diagnostic Test
Intervention Name(s)
Solid pancreatic mass lesion biopsy
Other Intervention Name(s)
biopsy, fine needle biopsy, fine needle aspiration
Intervention Description
The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.
Primary Outcome Measure Information:
Title
Degree of cellularity in biopsy sample
Description
Compare the degree of cellularity of the obtained tissue in the biopsy sample between the four FNB needles in patients undergoing EUS-guided sampling of pancreatic masses using the three different sampling techniques. Cellularity is defined as the proportion of core tissue to total specimen area.
Time Frame
3 days
Secondary Outcome Measure Information:
Title
Diagnostic adequacy of the biopsy sample
Description
Documentation of the presence of adequate tissue material (pancreatic parenchyma and tumor if applicable) in the biopsy sample.
Time Frame
1 day
Title
Specimen bloodiness in biopsy sample
Description
Measured as the area of bloodiness in the biopsy sample, with calculation as a percentage in the microscopic field.
Time Frame
1 day
Title
Presence of crush artefact in biopsy sample
Description
Documenting the presence or absence of crush artefact in the biopsy sample. If present, it is measured as the area of artefact in biopsy sample, with calculation as a percentage in relation to the total sample area.
Time Frame
1 day
Title
Technical failure
Description
Measured as the inability to successfully perform the fine needle biopsy using the assigned needle, due to any needle dysfunction.
Time Frame
1 day
Title
Adverse events
Description
The subject will be asked to report and medical records will be reviewed for any adverse events related to the procedure or the underlying disease.
Time Frame
7 days, 30 days, and 6 months
Title
Diagnostic operating characteristics
Description
Compare the diagnostic operating characteristics of the biopsy sample and detection of neoplasia (defined as sensitivity, specificity, negative predictive value, positive predictive value and accuracy) between the four FNB needles in patients undergoing EUS-guided sampling of pancreatic masses using the three different sampling techniques
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients referred for EUS-guided tissue acquisition of suspected or confirmed solid pancreatic mass lesions visualized on any radiological imaging Able and willing to provide written or verbal consent ≥ 18 years old Able to undergo conscious sedation for EUS procedure Exclusion Criteria: <18 years old Unable to obtain informed consent from the patient Medically unfit for sedation Pregnant patients No pancreatic mass lesions visualized on EUS Irreversible coagulopathy as determined by platelet count < 50,000/microL or International Normalized Ratio (INR) > 1.5 Unable to stop anti-platelet agents prior to the procedure
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shyam Varadarajulu, MD
Phone
407.303.2750
Email
shyam.varadarajulu.md@adventhealth.com
First Name & Middle Initial & Last Name or Official Title & Degree
Robin Barron-Nelson
Phone
321.946.2747
Email
robin.barron@flhosp.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shyam Varadarajulu, MD
Organizational Affiliation
AdventHealth
Official's Role
Principal Investigator
Facility Information:
Facility Name
AdventHealth Orlando
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Citations:
PubMed Identifier
20620274
Citation
Ngamruengphong S, Li F, Zhou Y, Chak A, Cooper GS, Das A. EUS and survival in patients with pancreatic cancer: a population-based study. Gastrointest Endosc. 2010 Jul;72(1):78-83, 83.e1-2. doi: 10.1016/j.gie.2010.01.072.
Results Reference
background
PubMed Identifier
22341257
Citation
Othman MO, Wallace MB. The role of endoscopic ultrasonography in the diagnosis and management of pancreatic cancer. Gastroenterol Clin North Am. 2012 Mar;41(1):179-88. doi: 10.1016/j.gtc.2011.12.014. Epub 2012 Jan 16.
Results Reference
background
PubMed Identifier
22248600
Citation
Hewitt MJ, McPhail MJ, Possamai L, Dhar A, Vlavianos P, Monahan KJ. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointest Endosc. 2012 Feb;75(2):319-31. doi: 10.1016/j.gie.2011.08.049.
Results Reference
background
PubMed Identifier
15100946
Citation
Varadarajulu S, Fraig M, Schmulewitz N, Roberts S, Wildi S, Hawes RH, Hoffman BJ, Wallace MB. Comparison of EUS-guided 19-gauge Trucut needle biopsy with EUS-guided fine-needle aspiration. Endoscopy. 2004 May;36(5):397-401. doi: 10.1055/s-2004-814316.
Results Reference
background
PubMed Identifier
26561917
Citation
Bang JY, Hawes R, Varadarajulu S. A meta-analysis comparing ProCore and standard fine-needle aspiration needles for endoscopic ultrasound-guided tissue acquisition. Endoscopy. 2016 Apr;48(4):339-49. doi: 10.1055/s-0034-1393354. Epub 2015 Nov 12.
Results Reference
background
PubMed Identifier
28988195
Citation
Bang JY, Hebert-Magee S, Navaneethan U, Hasan MK, Hawes R, Varadarajulu S. EUS-guided fine needle biopsy of pancreatic masses can yield true histology. Gut. 2018 Dec;67(12):2081-2084. doi: 10.1136/gutjnl-2017-315154. Epub 2017 Oct 7. No abstract available.
Results Reference
background
PubMed Identifier
29305893
Citation
Bang JY, Hebert-Magee S, Navaneethan U, Hasan MK, Hawes R, Varadarajulu S. Randomized trial comparing the Franseen and Fork-tip needles for EUS-guided fine-needle biopsy sampling of solid pancreatic mass lesions. Gastrointest Endosc. 2018 Jun;87(6):1432-1438. doi: 10.1016/j.gie.2017.11.036. Epub 2018 Jan 3.
Results Reference
background
PubMed Identifier
30403966
Citation
Lee KY, Cho HD, Hwangbo Y, Yang JK, Han SJ, Choi HJ, Lee YN, Cha SW, Moon JH, Cho YD, Park SH, Lee TH. Efficacy of 3 fine-needle biopsy techniques for suspected pancreatic malignancies in the absence of an on-site cytopathologist. Gastrointest Endosc. 2019 Apr;89(4):825-831.e1. doi: 10.1016/j.gie.2018.10.042. Epub 2018 Nov 4.
Results Reference
background
PubMed Identifier
29272906
Citation
Saxena P, El Zein M, Stevens T, Abdelgelil A, Besharati S, Messallam A, Kumbhari V, Azola A, Brainard J, Shin EJ, Lennon AM, Canto MI, Singh VK, Khashab MA. Stylet slow-pull versus standard suction for endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic lesions: a multicenter randomized trial. Endoscopy. 2018 May;50(5):497-504. doi: 10.1055/s-0043-122381. Epub 2017 Dec 22.
Results Reference
background
PubMed Identifier
24429514
Citation
Nakai Y, Isayama H, Chang KJ, Yamamoto N, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Yamamoto K, Kawakubo K, Kogure H, Sasaki T, Hirano K, Tanaka M, Tada M, Fukayama M, Koike K. Slow pull versus suction in endoscopic ultrasound-guided fine-needle aspiration of pancreatic solid masses. Dig Dis Sci. 2014 Jul;59(7):1578-85. doi: 10.1007/s10620-013-3019-9. Epub 2014 Jan 16.
Results Reference
background
Citation
Chow, S.C.; Shao, J.; Wang, H. 2008. Sample Size Calculations in Clinical Research, 2nd Edition. Chapman & Hall/CRC. Boca Raton, FL. Pages 99-100.
Results Reference
background
PubMed Identifier
32652307
Citation
Young Bang J, Krall K, Jhala N, Singh C, Tejani M, Arnoletti JP, Navaneethan U, Hawes R, Varadarajulu S. Comparing Needles and Methods of Endoscopic Ultrasound-Guided Fine-Needle Biopsy to Optimize Specimen Quality and Diagnostic Accuracy for Patients With Pancreatic Masses in a Randomized Trial. Clin Gastroenterol Hepatol. 2021 Apr;19(4):825-835.e7. doi: 10.1016/j.cgh.2020.06.042. Epub 2020 Jul 8.
Results Reference
derived

Learn more about this trial

Fine Needle Biopsy of Solid Pancreatic Mass Lesions

We'll reach out to this number within 24 hrs